Institutional Investor Sentiment About Anika Therapeutics Inc (NASDAQ:ANIK) Increased

May 17, 2018 - By Jimmy Baldridge

Anika Therapeutics, Inc. (NASDAQ:ANIK) Logo

Sentiment for Anika Therapeutics Inc (NASDAQ:ANIK)

Anika Therapeutics Inc (NASDAQ:ANIK) institutional sentiment decreased to 1.37 in 2017 Q4. Its down -0.05, from 1.42 in 2017Q3. The ratio has worsened, as 78 active investment managers opened new and increased positions, while 57 decreased and sold their holdings in Anika Therapeutics Inc. The active investment managers in our partner’s database now hold: 12.26 million shares, down from 12.29 million shares in 2017Q3. Also, the number of active investment managers holding Anika Therapeutics Inc in their top 10 positions was flat from 2 to 2 for the same number . Sold All: 12 Reduced: 45 Increased: 54 New Position: 24.

Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company has market cap of $575.51 million. The firm develops, makes, and commercializes therapeutic products based on its proprietary hyaluronic acid technology. It has a 18.5 P/E ratio. The Company’s orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a woven gauze used as a bone graft wrap; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment.

The stock decreased 1.96% or $0.78 during the last trading session, reaching $39.03. About 161,981 shares traded or 12.50% up from the average. Anika Therapeutics, Inc. (NASDAQ:ANIK) has risen 15.35% since May 17, 2017 and is uptrending. It has outperformed by 3.80% the S&P500.

Analysts await Anika Therapeutics, Inc. (NASDAQ:ANIK) to report earnings on July, 25. They expect $0.29 EPS, down 61.84 % or $0.47 from last year’s $0.76 per share. ANIK’s profit will be $4.28M for 33.65 P/E if the $0.29 EPS becomes a reality. After $0.11 actual EPS reported by Anika Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 163.64 % EPS growth.

Healthinvest Partners Ab holds 13.04% of its portfolio in Anika Therapeutics, Inc. for 114,600 shares. Thomson Horstmann & Bryant Inc owns 243,090 shares or 1.73% of their US portfolio. Moreover, Ami Asset Management Corp has 1.03% invested in the company for 276,041 shares. The Virginia-based Capital Management Corp Va has invested 0.89% in the stock. Kayne Anderson Rudnick Investment Management Llc, a California-based fund reported 1.67 million shares.

Anika Therapeutics, Inc. (NASDAQ:ANIK) Ratings Coverage

Ratings analysis reveals 100% of Anika Therapeutics Inc’s analysts are positive. Out of 3 Wall Street analysts rating Anika Therapeutics Inc, 3 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. ANIK was included in 4 notes of analysts from December 28, 2017. The rating was upgraded by Barrington Research to “Outperform” on Friday, May 4. The firm earned “Market Perform” rating on Friday, February 23 by Barrington Research. As per Wednesday, January 24, the company rating was upgraded by First Analysis.

More notable recent Anika Therapeutics, Inc. (NASDAQ:ANIK) news were published by: Nasdaq.com which released: “Mid-Afternoon Market Update: Dow Turns Positive; Anika Therapeutics Shares Fall Following Disappointing Q1 Results” on May 03, 2018, also Businesswire.com with their article: “Anika to Showcase Commercial and Pipeline Portfolio at 18th Bi-Annual European Society for Sports Traumatology …” published on May 08, 2018, Benzinga.com published: “The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap” on April 29, 2018. More interesting news about Anika Therapeutics, Inc. (NASDAQ:ANIK) were released by: Benzinga.com and their article: “Benzinga’s Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down” published on May 04, 2018 as well as Globenewswire.com‘s news article titled: “Report: Developing Opportunities within AMC Networks, JELD-WEN Holding, Blueprint Medicines, Northwest …” with publication date: May 01, 2018.

Anika Therapeutics, Inc. (NASDAQ:ANIK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: